We have located links that may give you full text access.
Diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) assay for detecting primary and recurrent urinary bladder cancer.
Proteomics. Clinical Applications 2019 January 12
PURPOSE: To evaluate the diagnostic and prognostic performance of Secreted Protein Acidic and Rich in Cysteine (SPARC) in detecting urinary bladder cancer (UBC).
METHODS: Among the Integrated Study on Bladder Cancer (ISBLaC) study participants (n = 571; mean age:69.4±12.2 years), two cross-sectional studies assessed SPARC diagnostic performance in primary (n = 264, including 179 primary UBC patients and 85 urological controls) and recurrent (n = 307, including 56 recurrent UBC patients and 251 non-recurrent controls) UBC. SPARC prognostic performance was evaluated in a nested cohort (n = 250) prospectively monitored for disease relapse for 80 months. Baseline urine samples were analyzed blindly using a commercially available SPARC ELISA assay, characterized for its analytical performance according to clinical test regulatory requirements (R&D Manufactures Inc.).
RESULTS: While higher mean SPARC levels were detected in primary (p = 0.008) and recurrent (p<0.0001) UBC, the assay had limited diagnostic performance (AUC:0.593; 95% CI:0.524-0.663). SPARC positive patients undergoing disease monitoring were more likely to develop tumor relapse (age and gender Adjusted Hazard Ratio, Adj. HR:1.52; 95% CI:1.04-2.22) and progression (Adj. HR:1.83; 95% CI:1.02-3.27). However, prognostic performance was affected by hematuria.
CONCLUSIONS AND CLINICAL RELEVANCE: SPARC diagnostic performance appears insufficient for clinical implementation in primary and/or recurrent UBC. In patients undergoing disease monitoring, SPARC is a promising prognostic marker for tumor relapse and/or progression, but is affected by hematuria. This article is protected by copyright. All rights reserved.
METHODS: Among the Integrated Study on Bladder Cancer (ISBLaC) study participants (n = 571; mean age:69.4±12.2 years), two cross-sectional studies assessed SPARC diagnostic performance in primary (n = 264, including 179 primary UBC patients and 85 urological controls) and recurrent (n = 307, including 56 recurrent UBC patients and 251 non-recurrent controls) UBC. SPARC prognostic performance was evaluated in a nested cohort (n = 250) prospectively monitored for disease relapse for 80 months. Baseline urine samples were analyzed blindly using a commercially available SPARC ELISA assay, characterized for its analytical performance according to clinical test regulatory requirements (R&D Manufactures Inc.).
RESULTS: While higher mean SPARC levels were detected in primary (p = 0.008) and recurrent (p<0.0001) UBC, the assay had limited diagnostic performance (AUC:0.593; 95% CI:0.524-0.663). SPARC positive patients undergoing disease monitoring were more likely to develop tumor relapse (age and gender Adjusted Hazard Ratio, Adj. HR:1.52; 95% CI:1.04-2.22) and progression (Adj. HR:1.83; 95% CI:1.02-3.27). However, prognostic performance was affected by hematuria.
CONCLUSIONS AND CLINICAL RELEVANCE: SPARC diagnostic performance appears insufficient for clinical implementation in primary and/or recurrent UBC. In patients undergoing disease monitoring, SPARC is a promising prognostic marker for tumor relapse and/or progression, but is affected by hematuria. This article is protected by copyright. All rights reserved.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app